MOUNJARO® 7.5mg KwikPen®, 1 Stk. (English Alternative)

Description

Name: MOUNJARO® 7.5mg KwikPen®, 1 Stk. (English Alternative)
Manufacturer: Eli Lilly and Company Limited
Active Substance(s): TIRZEPATIDE
Strength: 7.5 mg/dose
Package Content: 1 pen(s)

MOUNJARO® 7.5mg KwikPen offers a convenient, pre-filled injection designed for once-weekly use. This dosage provides a balanced option for individuals progressing in their treatment plan, combining ease of administration with consistent delivery. The pen’s design supports accurate dosing, helping patients maintain adherence while working toward improved metabolic health outcomes. For those looking to buy MOUNJARO® 7.5mg KwikPen online, the Maylips support team is more than happy to provide guidance.

MOUNJARO® 7.5mg KwikPen contains tirzepatide as its active substance — a synthetic dual incretin receptor agonist that engages both GIP and GLP-1 pathways to support glycemic control and, where locally indicated, chronic weight management. Tirzepatide is the International Nonproprietary Name (INN) for the active molecule, while MOUNJARO® is the proprietary brand name Eli Lilly and Company uses across all approved strengths. Both terms refer to the same pharmaceutical compound; the distinction lies between the generic scientific name and the commercial product presentation [3].

The 7.5mg strength is the intermediate step in the MOUNJARO® titration sequence, sitting between the 5mg and 10mg doses. It is prescribed when a patient has completed the 5mg stage and requires additional therapeutic effect before any clinical consideration of further escalation. The decision to progress to 7.5mg should be based on the patient’s individual tolerability and the degree of glycemic or weight-management response achieved at the prior dose [4].

Each KwikPen contains four pre-filled doses, each delivering 7.5mg of tirzepatide in 0.6mL, for once-weekly subcutaneous administration [3]. The fixed-dose format eliminates the need for manual preparation and supports consistent dosing, making it suitable for continued outpatient therapy under the clinical supervision of a doctor, pharmacist, or nurse. Healthcare professionals should consult current prescribing information for applicable pack sizes, storage requirements, and dispensing conditions in their region [4].

Tirzepatide is the first approved agent in its class to simultaneously activate both GIP and GLP-1 receptors via distinct binding domains within a single synthetic peptide [2]. This dual-receptor engagement sets it apart from conventional GLP-1 receptor agonists, which target only one incretin pathway, and underpins its effects on glucose regulation, body weight, and broader metabolic function.

Key pharmacological actions include:

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. These combined effects reduce fasting and postprandial blood glucose levels and support satiety in adults with type 2 diabetes [2].
• GIP receptor activation: Enhances insulin responsiveness and modulates adipose tissue metabolism. Evidence suggests that GIP receptor activity may also improve gastrointestinal tolerability relative to GLP-1 monotherapy, potentially attenuating the frequency or severity of nausea, diarrhea, and vomiting [2].
• Glucose-dependent mechanism: Because insulin secretion is triggered by elevated blood glucose concentrations, the standalone risk of hypoglycemia is comparatively low. This risk increases meaningfully when tirzepatide is co-administered with insulin or sulfonylureas, and blood sugar monitoring is required in those settings [4].

Clinical evidence from the SURPASS-2 trial demonstrates that tirzepatide produced greater reductions in HbA1c and body weight than semaglutide in adults with type 2 diabetes [2]. Data from the SURMOUNT-1 program further support its role in achieving meaningful body weight reduction among eligible adults receiving chronic weight management treatment [1]. Healthcare professionals should consult the full prescribing information for complete pharmacological data, titration schedules, and guidance on drug interactions before initiating or adjusting therapy [4].

MOUNJARO® 7.5mg KwikPen® is a multi-dose pre-filled injection device designed to deliver a fixed dose of 7.5 mg tirzepatide in 0.6 mL once weekly. It is indicated for the treatment of adults with type 2 diabetes mellitus and for weight management in patients with obesity or overweight conditions linked to health risks. Each KwikPen® contains 2.4 mL solution with a total of 30 mg tirzepatide, providing four weekly doses. The formulation is a clear, colourless to slightly yellow liquid and is administered by subcutaneous injection into the abdomen, thigh, or upper arm.

• Provides 4 doses of 7.5 mg each (0.6 mL per injection)

• Once-weekly administration supports adherence and convenience

• Used as a titration step before reaching higher maintenance doses

MOUNJARO® 7.5mg KwikPen® is provided in a KwikPen® device containing 2.4 mL solution, sufficient for four doses. Packs may include either a single pen or a set of three pens, with pen needles not included and requiring separate purchase.

The solution contains tirzepatide as the active pharmaceutical ingredient, along with carefully selected excipients to maintain stability and sterility.

• Active substance: Tirzepatide 7.5 mg per 0.6 mL injection

• Total pen content: 30 mg tirzepatide in 2.4 mL (12.5 mg/mL concentration)

• Excipients: Disodium hydrogen phosphate heptahydrate, benzyl alcohol (~5.4 mg per dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections

• Sodium content: Less than 1 mmol (23 mg) sodium per dose, essentially sodium-free

• Appearance: Clear, colourless to slightly yellow solution

MOUNJARO® 7.5mg is used in the treatment of type 2 diabetes mellitus in adults who require improved glycaemic control, either as monotherapy or in combination with other antidiabetic medicines. It is also indicated for weight management, including weight reduction and maintenance, in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² if they have weight-related conditions such as hypertension, cardiovascular disease, dyslipidaemia, obstructive sleep apnoea, or prediabetes.

• Indications:

  • Management of type 2 diabetes mellitus

  • Weight loss and maintenance in adults with BMI ≥30 kg/m²

  • Overweight patients (BMI ≥27 kg/m²) with comorbidities

• Contraindications:

  • Known hypersensitivity to tirzepatide or excipients

  • Not recommended in severe gastrointestinal diseases (e.g., gastroparesis)

  • Use with caution in patients with a history of pancreatitis

• Side effects:

  • Very common: Nausea, vomiting, diarrhoea, abdominal pain, constipation

  • Common: Loss of appetite, dyspepsia, dizziness, fatigue, mild injection-site reactions

  • Occasional: Gallbladder events such as gallstones or cholecystitis

  • Rare: Acute pancreatitis, serious allergic reactions (e.g., angioedema, anaphylaxis)

  • Laboratory changes: Elevated amylase and lipase levels

1. MOUNJARO® 7.5mg is injected once weekly at a consistent time, with or without meals. The dose should be administered into the abdomen, thigh, or upper arm, and injection sites should be rotated with each dose to prevent irritation. Patients can self-administer following proper training.

   • Dosing protocol:

     • Start at 2.5 mg weekly for 4 weeks, then gradually escalate

     • 7.5 mg serves as an intermediate titration dose before higher levels

     • Maximum dose: 15 mg once weekly

   • Missed dose instructions:

     • If ≤4 days late: inject as soon as possible

     • If >4 days late: skip and continue with the next scheduled dose

   • Injection method:

     • Always attach a new sterile needle before use

     • Dial to 1 in the dose window (=0.6 mL dose)

     • Inject subcutaneously, hold for 5 seconds until window shows 0

     • Remove and discard the needle in a sharps container

   Correct storage is critical to preserve product safety and effectiveness.

   • Unopened pens: Store refrigerated at 2–8 °C

   • Do not freeze; discard if frozen

   • After first use: May be stored at ≤30 °C for up to 30 days

   • Discard after 30 days, even if liquid remains

   • Keep out of reach of children

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.